For most of 2023 and 2024, pharmacies were legally allowed to compound copies of semaglutide and tirzepatide because both drugs were on the FDA's official drug shortage list. That legal pathway has been closing for a while, and in the spring of 2026 the FDA moved to shut it for good.
What the FDA Actually Proposed
On April 30, 2026, the FDA proposed a rule that would formally exclude semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that 503B outsourcing facilities are allowed to compound. If finalized, the rule would bar large-scale outsourcing facilities from compounding these three GLP-1 medicines from bulk substances under any circumstances, permanently, regardless of whether a shortage returns in the future. The agency opened a public comment period that ran through June 29, 2026.
This Builds on an Existing Shortage Determination
The proposal did not come out of nowhere. Tirzepatide's shortage was first declared resolved in October 2024 and reaffirmed in December 2024, with a short compounding wind-down window. Semaglutide's shortage was declared resolved in February 2025. Once a drug is off the shortage list, the large-scale, shortage-based compounding pathway for it closes automatically under existing law. The April 2026 proposal is different: it would remove the possibility of that pathway ever reopening for these three drugs specifically, even if a shortage were to recur.
A Narrower Exception Still Exists, for Now
Separately, in an April 1, 2026 policy clarification, the FDA addressed a smaller-scale pathway under section 503A, which covers traditional compounding pharmacies rather than large outsourcing facilities. The agency said it does not generally intend to take enforcement action against a 503A pharmacy that compounds a drug that is "essentially a copy" of a commercial product, provided it fills four or fewer prescriptions of that compounded product in a given calendar month. That is a narrow, patient-specific allowance, not a basis for the kind of mass-market compounding that was common during the shortage years, and it applies only to individualized prescriptions, not bulk production.
What This Means for Access and Cost
Brand-name semaglutide (marketed as Ozempic, Wegovy, and Rybelsus) and tirzepatide (marketed as Mounjaro and Zepbound) remain FDA-approved medications, available by prescription, and unaffected in terms of their own approval status. What changes is the compounded alternative that many patients turned to when brand-name products were scarce or when insurance did not cover them. Compounded versions have often run in the range of $150 to $300 a month, compared with list prices exceeding $1,000 a month for brand-name products absent insurance coverage or manufacturer savings programs. If the rule is finalized as proposed, that lower-cost compounded option would no longer be legally available at scale, pushing patients toward brand-name pricing, insurance coverage, manufacturer assistance programs, or the narrow 503A patient-specific exception described above.
Where Things Stand Right Now
As of this writing, this is a proposed rule, not a final one. The public comment period closed on June 29, 2026, and the FDA has not yet announced a final rule or an effective date. Compounding of these three drugs outside the narrow 503A allowance is already effectively prohibited under current shortage-list rules, so the practical effect for most patients has already been felt; the proposed rule would make that prohibition permanent and remove any future shortage-based reopening of the large-scale pathway.
Talk to Your Doctor About Your Options
If you currently rely on a compounded GLP-1 product, this is a reasonable moment to talk with your prescriber about what happens if that option becomes unavailable, including whether you qualify for manufacturer savings programs, whether your insurance covers the brand-name product, and whether a different treatment approach makes sense for your situation. This article is not a substitute for that conversation, and it isn't medical advice about whether to start, stop, or switch any medication.